Merck& Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.Reuters Health Information (Source: Medscape Allergy Headlines)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Tf0NRm
Δευτέρα 25 Φεβρουαρίου 2019
Merck to Buy Immunotherapy Developer Immune Design for $300 Mln Merck to Buy Immunotherapy Developer Immune Design for $300 Mln
Merck to Buy Immunotherapy Developer Immune Design for $300 Mln Merck to Buy Immunotherapy Developer Immune Design for $300 Mln
Merck& Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.Reuters Health Information (Source: Medscape Allergy Headlines)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Tf0NRm
Epidemiology of otorhinolaryngologic emergencies in a secondary hospital: analysis of 64,054 cases
Abstract
Purpose
To determine the incidence and distribution of care in relation to urgent otorhinolaryngologic pathologies by the different medical specialist units.
Methods
A descriptive, observational and retrospective study was conducted of patients seen by the Emergency Service at a secondary hospital over the course of 7 years (2011–2017).
Results
A total of 546,701 patients were seen during the period in question, of which 64,054 presented with otorhinolaryngologic symptoms. The attendance rate was 450/1000 inhabitants/year. The most frequent diagnoses were upper respiratory tract infection, with 13,639 cases (21.3%), tonsillopharyngitis, with 10,150 cases (15.8%) and vertigo/dizziness with 8761 cases (13.7%). Patients seen by the Hospital Emergency Service physicians and those referred to the Otorhinolaryngology or Paediatric Units were analysed both together and separately. The Hospital Emergency Service dealt with 77.1% of the cases, and referred 15.4% to the Otorhinolaryngology Unit and 7.5% to the Paediatrics Unit. Within the subgroup of patients referred to the Otorhinolaryngology Unit, the most frequent diagnoses were problems related to inflammatory ear disease (25.6%), followed by cervicofacial trauma (15.4%) and bleeding with otorhinolaryngologic symptoms (12.5%). The percentage of hospital admissions for the entire sample was 3%, while for patients referred to the Otorhinolaryngology Unit this figure was 6.8%.
Conclusions
A large percentage of patients presenting at the Hospital Emergency Service do so with otorhinolaryngologic symptoms, and the vast majority are treated effectively by the physicians in that service and are referred to the specialist services on the basis of sound criteria.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2H0Q46z
Epidemiology of otorhinolaryngologic emergencies in a secondary hospital: analysis of 64,054 cases
Abstract
Purpose
To determine the incidence and distribution of care in relation to urgent otorhinolaryngologic pathologies by the different medical specialist units.
Methods
A descriptive, observational and retrospective study was conducted of patients seen by the Emergency Service at a secondary hospital over the course of 7 years (2011–2017).
Results
A total of 546,701 patients were seen during the period in question, of which 64,054 presented with otorhinolaryngologic symptoms. The attendance rate was 450/1000 inhabitants/year. The most frequent diagnoses were upper respiratory tract infection, with 13,639 cases (21.3%), tonsillopharyngitis, with 10,150 cases (15.8%) and vertigo/dizziness with 8761 cases (13.7%). Patients seen by the Hospital Emergency Service physicians and those referred to the Otorhinolaryngology or Paediatric Units were analysed both together and separately. The Hospital Emergency Service dealt with 77.1% of the cases, and referred 15.4% to the Otorhinolaryngology Unit and 7.5% to the Paediatrics Unit. Within the subgroup of patients referred to the Otorhinolaryngology Unit, the most frequent diagnoses were problems related to inflammatory ear disease (25.6%), followed by cervicofacial trauma (15.4%) and bleeding with otorhinolaryngologic symptoms (12.5%). The percentage of hospital admissions for the entire sample was 3%, while for patients referred to the Otorhinolaryngology Unit this figure was 6.8%.
Conclusions
A large percentage of patients presenting at the Hospital Emergency Service do so with otorhinolaryngologic symptoms, and the vast majority are treated effectively by the physicians in that service and are referred to the specialist services on the basis of sound criteria.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2H0Q46z
Validation of web‐based thyroid imaging reporting and data system in atypia or follicular lesion of undetermined significance thyroid nodules
Abstract
Background
Atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) show variable malignancy risk. We validated the web‐based predictive models and the scoring system by the American College of Radiology (ACR) for AUS/FLUS nodules to stratify the malignancy risk.
Methods
From January 2011 to November 2014, 275 consecutive nodules diagnosed as AUS/FLUS were enrolled. The discrimination and calibration ability of a web‐based scoring with inclusion of biopsy result and sonographic features, old web‐based scoring model without biopsy result, and ACR models were assessed.
Results
The areas under the receiver operating characteristic curve of the validation set were 0.670 for the new web‐based model, 0.710 for the old web‐based model, and 0.732 for the ACR scoring risk‐stratification model. All models were well calibrated.
Conclusion
The web‐based scoring risk‐stratification model using the combined information of ultrasonography features and biopsy result for AUS/FLUS nodules to stratify malignancy risk presents an acceptable predictive accuracy.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2XoCAXR
Merck to Buy Immunotherapy Developer Immune Design for $300 Mln Merck to Buy Immunotherapy Developer Immune Design for $300 Mln
Merck& Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.Reuters Health Information (Source: Medscape Allergy Headlines)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Tf0NRm
Extreme allergies: 'I couldn't even eat an apple'
How do you cope when allergies prevent you from eating a long list of foods? (Source: BBC News | Health | UK Edition)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EtAr67
Eating small amounts of peanut after immunotherapy may extend allergy treatment benefits
(University of North Carolina Health Care) Regular dietary peanut consumption after completing oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) for peanut allergy may provide continued protection against accidental exposures to the allergen, according to a new study led by Edwin Kim, MD, who presented the findings at the annual American Academy of Allergy, Asthma and Immunology (AAAAI) conference in San Francisco. (Source: EurekAlert! - Medicine and Health)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2TdYI8b
Merck to Buy Immunotherapy Developer Immune Design for $300 Mln Merck to Buy Immunotherapy Developer Immune Design for $300 Mln
Merck& Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.Reuters Health Information (Source: Medscape Allergy Headlines)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Tf0NRm
Extreme allergies: 'I couldn't even eat an apple'
How do you cope when allergies prevent you from eating a long list of foods? (Source: BBC News | Health | UK Edition)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EtAr67
Eating small amounts of peanut after immunotherapy may extend allergy treatment benefits
(University of North Carolina Health Care) Regular dietary peanut consumption after completing oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) for peanut allergy may provide continued protection against accidental exposures to the allergen, according to a new study led by Edwin Kim, MD, who presented the findings at the annual American Academy of Allergy, Asthma and Immunology (AAAAI) conference in San Francisco. (Source: EurekAlert! - Medicine and Health)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2TdYI8b
Validation of web‐based thyroid imaging reporting and data system in atypia or follicular lesion of undetermined significance thyroid nodules
Abstract
Background
Atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) show variable malignancy risk. We validated the web‐based predictive models and the scoring system by the American College of Radiology (ACR) for AUS/FLUS nodules to stratify the malignancy risk.
Methods
From January 2011 to November 2014, 275 consecutive nodules diagnosed as AUS/FLUS were enrolled. The discrimination and calibration ability of a web‐based scoring with inclusion of biopsy result and sonographic features, old web‐based scoring model without biopsy result, and ACR models were assessed.
Results
The areas under the receiver operating characteristic curve of the validation set were 0.670 for the new web‐based model, 0.710 for the old web‐based model, and 0.732 for the ACR scoring risk‐stratification model. All models were well calibrated.
Conclusion
The web‐based scoring risk‐stratification model using the combined information of ultrasonography features and biopsy result for AUS/FLUS nodules to stratify malignancy risk presents an acceptable predictive accuracy.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2XoCAXR
Merck to Buy Immunotherapy Developer Immune Design for $300 Mln Merck to Buy Immunotherapy Developer Immune Design for $300 Mln
Merck& Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.Reuters Health Information (Source: Medscape Allergy Headlines)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Tf0NRm
Extreme allergies: 'I couldn't even eat an apple'
How do you cope when allergies prevent you from eating a long list of foods? (Source: BBC News | Health | UK Edition)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EtAr67
Eating small amounts of peanut after immunotherapy may extend allergy treatment benefits
(University of North Carolina Health Care) Regular dietary peanut consumption after completing oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) for peanut allergy may provide continued protection against accidental exposures to the allergen, according to a new study led by Edwin Kim, MD, who presented the findings at the annual American Academy of Allergy, Asthma and Immunology (AAAAI) conference in San Francisco. (Source: EurekAlert! - Medicine and Health)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2TdYI8b
Merck to Buy Immunotherapy Developer Immune Design for $300 Mln Merck to Buy Immunotherapy Developer Immune Design for $300 Mln
Merck& Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.Reuters Health Information (Source: Medscape Allergy Headlines)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Tf0NRm
Extreme allergies: 'I couldn't even eat an apple'
How do you cope when allergies prevent you from eating a long list of foods? (Source: BBC News | Health | UK Edition)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EtAr67
Eating small amounts of peanut after immunotherapy may extend allergy treatment benefits
(University of North Carolina Health Care) Regular dietary peanut consumption after completing oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) for peanut allergy may provide continued protection against accidental exposures to the allergen, according to a new study led by Edwin Kim, MD, who presented the findings at the annual American Academy of Allergy, Asthma and Immunology (AAAAI) conference in San Francisco. (Source: EurekAlert! - Medicine and Health)
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2TdYI8b
Κυριακή 24 Φεβρουαρίου 2019
The effects of endoscopic sinus surgery on pulmonary function in chronic rhinosinusitis patients with asthma: a systematic review and meta-analysis
Abstract
Purpose
Evidences showed improvements in clinical asthma outcomes following endoscopic sinus surgery (ESS) in chronic rhinosinusitis (CRS) patients with asthma. However, pulmonary function benefits have remained controversial up to date. The goal of this study was to conduct a systematic review and meta-analysis to investigate the effects of ESS on pulmonary function tests in CRS patients with asthma.
Methods
Pubmed, Embase and Cochrane Library were searched up to March 2018 to obtain relevant studies. The researches that evaluated the effects of ESS on pulmonary function in CRS patients with asthma and had at least one parameter of pulmonary function tests before and after surgery were included in the study.
Results
A total of 13 studies containing 421 patients satisfied the eligibility after judgment by 2 reviewers. These included three RCTs and ten case series. The heterogeneity in parameters of spirometry and difference in data presented forms across studies along with the lack of standard deviation of some data make it difficult to synthesize results. If data were unavailable for meta-analyses, descriptive statistics were used to report study outcomes. After qualitative and quantitative analysis, the weighted mean change after ESS in forced expiratory flow between 25% and 75% of vital capacity (FEF25–75%) was 0.21 L/s (95% CI 0.12–0.30); eight of ten studies supported that forced expiratory volume at 1 s (FEV1) improved after ESS; five of six studies supported that peak expiratory flow (PEF) improved after ESS. However, strength of evidence is generally low to insufficient.
Conclusion
A generally low-quality evidence supports the association between ESS and improvements in FEF25–75%, FEV1 and PEF. A few studies met inclusion criteria for meta-analysis, which indicates the need for more high-quality studies to determine the effect of ESS.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2VbjpPs
The effects of endoscopic sinus surgery on pulmonary function in chronic rhinosinusitis patients with asthma: a systematic review and meta-analysis
Abstract
Purpose
Evidences showed improvements in clinical asthma outcomes following endoscopic sinus surgery (ESS) in chronic rhinosinusitis (CRS) patients with asthma. However, pulmonary function benefits have remained controversial up to date. The goal of this study was to conduct a systematic review and meta-analysis to investigate the effects of ESS on pulmonary function tests in CRS patients with asthma.
Methods
Pubmed, Embase and Cochrane Library were searched up to March 2018 to obtain relevant studies. The researches that evaluated the effects of ESS on pulmonary function in CRS patients with asthma and had at least one parameter of pulmonary function tests before and after surgery were included in the study.
Results
A total of 13 studies containing 421 patients satisfied the eligibility after judgment by 2 reviewers. These included three RCTs and ten case series. The heterogeneity in parameters of spirometry and difference in data presented forms across studies along with the lack of standard deviation of some data make it difficult to synthesize results. If data were unavailable for meta-analyses, descriptive statistics were used to report study outcomes. After qualitative and quantitative analysis, the weighted mean change after ESS in forced expiratory flow between 25% and 75% of vital capacity (FEF25–75%) was 0.21 L/s (95% CI 0.12–0.30); eight of ten studies supported that forced expiratory volume at 1 s (FEV1) improved after ESS; five of six studies supported that peak expiratory flow (PEF) improved after ESS. However, strength of evidence is generally low to insufficient.
Conclusion
A generally low-quality evidence supports the association between ESS and improvements in FEF25–75%, FEV1 and PEF. A few studies met inclusion criteria for meta-analysis, which indicates the need for more high-quality studies to determine the effect of ESS.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2VbjpPs